The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility

Publisher： Bentham Science Publishers

E-ISSN： 1875-6204|3|1|9-19

ISSN： 1570-1603

Source： Current Pharmacogenomics, Vol.3, Iss.1, 2005-01, pp. : 9-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis

By Wu Huizhe   Kang Hui   Liu Yong   Xiao Qinghuan   Zhang Yining   Sun Mingjun   Liu Duo   Wang Zhe   Zhao Haishan   Yao Weifan   Jia Tianhong   Wang Enhua   Zheng Zhihong   Wei Minjie  

Pharmacogenomics, Vol. 14, Iss. 8, 2013-06 ,pp. : 897-911

Future Medicine

Access to resources Recommend Favorite

Olaparib, PARP1 inhibitor in ovarian cancer

By Marchetti Claudia   Imperiale Ludovica   Gasparri Maria Luisa   Palaia Innocenza   Pignata Sandro   Boni Terenzio   Bellati Filippo   Benedetti Panici Pierluigi  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1575-1584

Informa Healthcare

Access to resources Recommend Favorite

Discussion of PARP inhibitors in cancer therapy

By Wielgos Monica   Yang Eddy S  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 6, 2013-11 ,pp. : 755-766

Future Science

Access to resources Recommend Favorite

PARP inhibitors in cancer therapy: an update

By Papeo Gianluca   Casale Elena   Montagnoli Alessia   Cirla Alessandra  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 503-514

Informa Healthcare

Access to resources Recommend Favorite

Parp Inhibitors for the Treatment of Ovarian Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 9, 2018-11 ,pp. : 877-893

Bentham Science Publishers

Access to resources Recommend Favorite